ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) is a phase 2, randomised interventional study registered as NCT06951646 by Second Xiangya Hospital of Central South University, with a registry enrolment figure of 70 participants, started 2026-03-10 and due to reach its primary completion in 2028-07-01. Interventions recorded: Ivonescimab; Docetaxel; Standard Treatment group. Conditions listed: Non Small Cell Lung Cancer; Immune Checkpoint Inhibitors (ICIs). Primary outcome: Progression-Free Survival (PFS) in ctDNA-Positive Population. Lung eligibility wording from the registry: "Patients with stage IIIB-IIIC and IV non-small cell lung cancer confirmed by histology or cytology that cannot be treated locally (TNM lung cancer staging of the 9th edition of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification);". Sites: China. No results are recorded here; the registry entry is the source.